1223 related articles for article (PubMed ID: 14578539)
21. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
22. Effects of antipsychotic medication on psychiatric service utilization and cost.
Rothbard A; Murrin MR; Jordan N; Kuno E; McFarland BH; Stroup TS; Morrissey JP; Stiles PG; Boothroyd RA; Merwin E; Shern DL
J Ment Health Policy Econ; 2005 Jun; 8(2):83-93. PubMed ID: 15998980
[TBL] [Abstract][Full Text] [Related]
23. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
24. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
[TBL] [Abstract][Full Text] [Related]
25. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
26. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.
Qiu Y; Fu AZ; Liu GG; Christensen DB
Appl Health Econ Health Policy; 2010; 8(3):167-77. PubMed ID: 20408601
[TBL] [Abstract][Full Text] [Related]
27. Implementing effectiveness research and improving care for schizophrenia in real-world settings.
Buckley PF; Miller A; Chiles JA; Sajatovic M
Am J Manag Care; 1999 Jun; 5 Spec No():SP47-56. PubMed ID: 10538860
[TBL] [Abstract][Full Text] [Related]
28. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
[TBL] [Abstract][Full Text] [Related]
30. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines.
Balu S
Clin Ther; 2009 Jul; 31(7):1581-94. PubMed ID: 19695408
[TBL] [Abstract][Full Text] [Related]
31. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
33. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
34. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
[TBL] [Abstract][Full Text] [Related]
35. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
[TBL] [Abstract][Full Text] [Related]
36. Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists.
Hamann J; Pfeiffer H; Leucht S; Kissling W
Pharmacopsychiatry; 2003 Nov; 36(6):309-12. PubMed ID: 14663656
[TBL] [Abstract][Full Text] [Related]
37. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
38. An analysis of the effects of organization and financing on the utilization and costs of public mental health services in san diego county.
Gilmer T
J Ment Health Policy Econ; 2007 Sep; 10(3):123-32. PubMed ID: 17890829
[TBL] [Abstract][Full Text] [Related]
39. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
40. Cost-outcome of anxiety treatment intervention in primary care in Hungary.
Zámbori J; Szádóczky E; Rózsa S; Füredi J
J Ment Health Policy Econ; 2002 Sep; 5(3):115-20. PubMed ID: 12728198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]